Call Now for a Free
Consultation
Queremos Ayudarle
Opioid Drug Maker Settles for $270 Million

Purdue Pharma, the maker of Oxycontin, and the Sackler family, founder and owner of Purdue Pharma, have agreed to settle a lawsuit brought by the Oklahoma attorney general for $270 million. OxyContin is an opioid painkiller that was falsely marketed as safe and less addictive. States across the nation are fighting an opioid epidemic that has killed hundreds of thousands and addicted even more. Thirty six states have brought suits.

The Oklahoma suit was filed against some of the nation’s leading producers of opioid pain medications and distributors. It alleges that the drug makers’ deceptive marketing over the past ten years has fueled the epidemic in Oklahoma. Defendants include Purdue Pharma, Johnson & Johnson, Teva Pharmaceuticals, Allergan and several others. The companies misled consumers into thinking that opioids are safe for long-term use.

Opioid Litigation

Opioid marketing by pharmaceutical companies having negligently fueled the national opioid epidemic is alleged in the more than 1,500 civil lawsuits around the country. U.S. District Judge Dan Polster, who is overseeing hundreds of the cases, has already scheduled the first trials. Terrell • Hogan is involved in this litigation. Opioids we have investigated for these claims include: Oxycodone and OxyContin.

If you or a loved one in Florida became addicted to or damaged by prescribed opioids or died from an opioid overdose, consider contacting Terrell Hogan Law at (904) 632-2424 for a free consultation.

Purdue Pharma to pay $270 million to settle historic Oklahoma opioid lawsuit

Opioid Marketing Linked to Opioid Deaths 

SHARE THIS ARTICLE

Get Help Now

Fill this out for a FREE case review.

Briefly type in what happened.
That’s all it takes to start the conversation, and, together, we will decide if Terrell Hogan Law is the firm to help you.
Sending your message means you are familiar with the purpose of this website.

Name(Required)
This field is for validation purposes and should be left unchanged.

About The Author